期刊文献+

基于生理药代动力学模型对盐酸莫西沙星有效性的研究 被引量:1

Evaluation on the efficacy of moxifloxacin hydrochloride based on physiological pharmacokinetic models
原文传递
导出
摘要 本研究基于生理药代动力学理论,建立和验证盐酸莫西沙星的体内药代模型,计算不同剂型在体内包括静脉血及肺、脾等不同器官的药物浓度-时间曲线,通过相应药代动力学参数结果与相关病原菌的最小抑菌浓度的比较,量化评价本品种及其制剂的有效性水平。结果表明,盐酸莫西沙星制剂在相应器官的抗感染有效性水平基本一致,品种制剂的生理药代动力学模型可以更为准确地描述抗感染药物在体内的吸收、分布、代谢和排泄过程,适用于这类药物的有效性评价工作,为相应科研与科学监管工作提供有力的研判依据。 This study is to establish and validation in vivo models of moxifloxacin based on the theory of physiologically based pharmacokinetics(PBPK),and then to predict the distribution of moxifloxacin in human venous return and organ such as lung,spleen and so on.The efficacy of moxifloxacin and its pharmaceutical preparations were quantified by comparing the pharmacokinetic parameters with the minimum inhibitory concentration of related pathogenic bacterium.The results showed that the anti-infection efficacy of pharmaceutical moxifloxacin preparation in the corresponding organs was basically the same.The PBPK model of moxifloxacin preparations can be more accurately described the pharmacokinetic of anti-infective drugs in human,it is suitable for the efficacy evaluation of anti-infective drugs and provides a strong basis for the corresponding scientific research and scientific supervision.
作者 高婕 冯芳 王立新 崇小萌 王晨 尹利辉 GAO Jie;FENG Fang;WANG Li-xin;CHONG Xiao-meng;WANG Chen;YIN Li-hui(National Institutes for Food and Drug Control,Beijing 102629,China;China Pharmaceutical University,Nanjing 210009,China)
出处 《药学学报》 CAS CSCD 北大核心 2022年第7期2153-2157,共5页 Acta Pharmaceutica Sinica
关键词 盐酸莫西沙星 生理药代动力学模型 有效性 药效学 moxifloxacin hydrochloride physiologically based pharmacokinetic model efficacy pharmacodynamics
  • 相关文献

参考文献3

二级参考文献71

  • 1Cruickshank JM. Beta-blockers and heart failure. Indian Heart J 2010; 62: 101-10.
  • 2de Groote P, Ennezat PV, Mouquet F. Bisoprolol in the treatment of chronic heart failure. Vasc Health Risk Manag 2007; 3: 431-9.
  • 3McGavin JK, Keating GM. Bisoprolol: a review of its use in chronic heart failure. Drugs 2002; 62:2677 -96.
  • 4Papadopulos DP, Papademetriou V. Low-dose fixed combination of bisoprolol/hydrochlorothiazide as first line for hypertension: a review of the rationale and clinical evidence. Angiology 2009; 60: 601-7.
  • 5CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
  • 6Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray J J, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-8.
  • 7Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 2010; 12: 974-82.
  • 8Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, etal. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341-62.
  • 9Brophy KM, Scariett-Ferguson H, Webber KS. Clinical drug therapy for Canadian practice. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2010.
  • 10Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet 1987; 13: 110-7.

共引文献27

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部